Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Novartis Ag ADR (NVS)

Novartis Ag ADR (NVS)
105.18 x 1 109.00 x 1
Post-market by (Cboe BZX)
107.52 +4.12 (+3.98%) 04/11/25 [NYSE]
105.18 x 1 109.00 x 1
Post-market 107.00 -0.52 (-0.48%) 17:35 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
104.69
Day High
108.13
Open 105.67
Previous Close 103.40 103.40
Volume 4,745,900 4,745,900
Avg Vol 3,148,700 3,148,700
Stochastic %K 43.10% 43.10%
Weighted Alpha +10.19 +10.19
5-Day Change +1.67 (+1.58%) +1.67 (+1.58%)
52-Week Range 92.35 - 120.92 92.35 - 120.92
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 219,770,880
  • Shares Outstanding, K 2,044,000
  • Annual Sales, $ 51,722 M
  • Annual Income, $ 11,941 M
  • EBIT $ 14,544 M
  • EBITDA $ 20,658 M
  • 60-Month Beta 0.56
  • Price/Sales 4.20
  • Price/Cash Flow 9.66
  • Price/Book 4.79

Options Overview Details

View History
  • Implied Volatility 33.54% ( -8.48%)
  • Historical Volatility 30.79%
  • IV Percentile 98%
  • IV Rank 68.07%
  • IV High 43.36% on 04/08/25
  • IV Low 12.60% on 05/16/24
  • Put/Call Vol Ratio 0.91
  • Today's Volume 1,941
  • Volume Avg (30-Day) 2,710
  • Put/Call OI Ratio 1.01
  • Today's Open Interest 66,692
  • Open Int (30-Day) 59,652

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.06
  • Number of Estimates 3
  • High Estimate 2.24
  • Low Estimate 1.96
  • Prior Year 1.80
  • Growth Rate Est. (year over year) +14.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
97.71 +10.03%
on 04/09/25
Period Open: 111.35
114.44 -6.05%
on 04/03/25
-3.83 (-3.44%)
since 03/11/25
3-Month
97.39 +10.40%
on 01/16/25
Period Open: 99.08
116.91 -8.03%
on 03/10/25
+8.44 (+8.52%)
since 01/10/25
52-Week
92.35 +16.43%
on 04/18/24
Period Open: 94.34
120.92 -11.08%
on 08/30/24
+13.18 (+13.97%)
since 04/11/24

Most Recent Stories

More News
Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More

This week, the European Commission granted marketing authorization to the expanded use of AbbVie’s ABBV Rinvoq and AstraZeneca’s AZN blockbuster cancer drugs, Imfinzi and Daiichi-Sankyo partnered,...

AZN : 66.29 (+2.19%)
NVS : 107.52 (+3.98%)
ABBV : 175.05 (+0.49%)
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure

This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) and the expanded...

AZN : 66.29 (+2.19%)
JNJ : 151.73 (+2.04%)
NVS : 107.52 (+3.98%)
PFE : 21.91 (+1.48%)
SNY : 51.50 (+3.71%)
FDA Grants Accelerated Approval to NVS Kidney Disease Drug

Novartis NVS obtains FDA approval of atrasentan, a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN)...

BAYRY : 5.9000 (+4.80%)
NVS : 107.52 (+3.98%)
GILD : 103.63 (+2.20%)
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer

J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated non-small...

AZN : 66.29 (+2.19%)
JNJ : 151.73 (+2.04%)
NVS : 107.52 (+3.98%)
The Top 3 Vanguard ETFs of 2025 (so Far) Share This 1 Striking Common Denominator

Baskin-Robbins has nothing on Vanguard. The ice cream chain is famous for offering 31 flavors to ice cream lovers. Meanwhile, Vanguard's family of exchange-traded funds (ETFs) features 90 choices for investors....

^MKRUSDT : 1,353.422 (+1.31%)
VEA : 49.41 (+2.74%)
SAP : 259.15 (+0.26%)
VOO : 490.55 (+1.76%)
VYMI : 70.91 (+2.68%)
NVS : 107.52 (+3.98%)
VGK : 68.29 (+2.68%)
^MKRBTC : 0.016160 (+1.56%)
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements

EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END

AZN : 66.29 (+2.19%)
LLY : 732.41 (+1.60%)
NVS : 107.52 (+3.98%)
ATNM : 1.3000 (+13.04%)
BMY : 50.71 (+0.50%)
5 Large Drug Stocks to Watch as Industry Recovers

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due to the better-than-expected fourth-quarter performance of large drugmakers and...

BAYRY : 5.9000 (+4.80%)
NVO : 64.73 (+5.75%)
NVS : 107.52 (+3.98%)
ABBV : 175.05 (+0.49%)
PFE : 21.91 (+1.48%)
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains

The medical sector is one of the major adopters of artificial intelligence (AI), which is currently being used to synthesize new compounds for drugs and create devices for more precise measurement and...

ABT : 126.88 (+1.91%)
BSX : 93.67 (+1.11%)
LLY : 732.41 (+1.60%)
NVS : 107.52 (+3.98%)
MDT : 82.90 (+0.44%)
FDA Approves Novartis Drug for Rare Kidney Disease Treatment

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication.The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria.C3G...

BAYRY : 5.9000 (+4.80%)
NVS : 107.52 (+3.98%)
GILD : 103.63 (+2.20%)
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease (“CD”), and Novartis’ NVS Fabhalta for its third indication, C3...

AZN : 66.29 (+2.19%)
JNJ : 151.73 (+2.04%)
NVS : 107.52 (+3.98%)
PFE : 21.91 (+1.48%)
SNY : 51.50 (+3.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy,...

See More

Key Turning Points

3rd Resistance Point 112.31
2nd Resistance Point 110.22
1st Resistance Point 108.87
Last Price 107.52
1st Support Level 105.43
2nd Support Level 103.34
3rd Support Level 101.99

See More

52-Week High 120.92
Fibonacci 61.8% 110.01
Last Price 107.52
Fibonacci 50% 106.63
Fibonacci 38.2% 103.26
52-Week Low 92.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar